全文获取类型
收费全文 | 26721篇 |
免费 | 2303篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 222篇 |
儿科学 | 979篇 |
妇产科学 | 760篇 |
基础医学 | 3719篇 |
口腔科学 | 548篇 |
临床医学 | 3361篇 |
内科学 | 4664篇 |
皮肤病学 | 357篇 |
神经病学 | 2789篇 |
特种医学 | 1021篇 |
外科学 | 2938篇 |
综合类 | 428篇 |
一般理论 | 40篇 |
预防医学 | 3189篇 |
眼科学 | 435篇 |
药学 | 2043篇 |
中国医学 | 53篇 |
肿瘤学 | 1516篇 |
出版年
2023年 | 148篇 |
2021年 | 441篇 |
2020年 | 333篇 |
2019年 | 425篇 |
2018年 | 536篇 |
2017年 | 433篇 |
2016年 | 430篇 |
2015年 | 508篇 |
2014年 | 707篇 |
2013年 | 1040篇 |
2012年 | 1413篇 |
2011年 | 1582篇 |
2010年 | 937篇 |
2009年 | 745篇 |
2008年 | 1431篇 |
2007年 | 1427篇 |
2006年 | 1394篇 |
2005年 | 1327篇 |
2004年 | 1213篇 |
2003年 | 1148篇 |
2002年 | 1095篇 |
2001年 | 628篇 |
2000年 | 604篇 |
1999年 | 588篇 |
1998年 | 336篇 |
1997年 | 263篇 |
1996年 | 238篇 |
1995年 | 217篇 |
1994年 | 198篇 |
1993年 | 188篇 |
1992年 | 443篇 |
1991年 | 455篇 |
1990年 | 449篇 |
1989年 | 403篇 |
1988年 | 411篇 |
1987年 | 424篇 |
1986年 | 336篇 |
1985年 | 369篇 |
1984年 | 285篇 |
1983年 | 248篇 |
1982年 | 180篇 |
1981年 | 160篇 |
1979年 | 277篇 |
1978年 | 229篇 |
1977年 | 158篇 |
1976年 | 175篇 |
1974年 | 188篇 |
1973年 | 181篇 |
1972年 | 161篇 |
1969年 | 170篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
D. Baker G. Pryce L. K. James K. Schmierer G. Giovannoni 《European journal of neurology》2020,27(2):221-228
Clinical trials are probably the most informative experiments to help an understanding of multiple sclerosis (MS) biology. Recent successes with CD20‐depleting antibodies have focused attention towards B cell subsets as important mediators in MS. The trial of tabalumab (NTC00882999), which inhibits B cell activation factor (BAFF), is reported and reviewed and this trial is contrasted with the trial on the inhibition of a proliferation‐inducing ligand (APRIL) and BAFF using atacicept (NCT00642902). Both tabalumab and atacicept induce depletion of mature B cells and inhibit antibody formation, but they fail to deplete memory B cells and do not inhibit relapsing MS. Atacicept is reported to augment memory B cell responses and may precipitate relapse, suggesting the importance of APRIL. However, BAFF inhibition can enhance peripheral blood memory B cell responses, which was not associated with augmented relapse. Although other interpretations are possible, these data further support the hypothesis that memory B cells may be of central importance in relapsing MS, as they are the major CD20+ B cell subset expressing APRIL receptors. They also suggest that quantitative and/or qualitative differences in B cell responses or other factors, such as an immune‐regulatory effect associated with APRIL, may be important in determining whether MS reactivates following neutralization of peripheral B cell maturation and survival factors. 相似文献
4.
William R. C. Knight Cara R. Baker Nyree Griffin Wahyu Wulaningsih Mark Kelly Andrew R. Davies James A. Gossage 《British journal of cancer》2021,124(10):1653
Background A high Mandard score implies a non-response to chemotherapy in oesophageal adenocarcinoma. However, some patients exhibit tumour volume reduction and a nodal response despite a high score. This study examines survival and recurrence patterns in these patients.Methods Clinicopathological factors were analysed using multivariable Cox regression assessing time to death and recurrence. Computed tomography-estimated tumour volume change was examined in a subgroup of consecutive patients.Results Five hundred and fifty-five patients were included. Median survival was 55 months (Mandard 1–3) and 21 months (Mandard 4 and 5). In the Mandard 4 and 5 group (332 patients), comparison between complete nodal responders and persistent nodal disease showed improved survival (90 vs 18 months), recurrence rates (locoregional 14.75 vs 28.74%, systemic 24.59 vs 48.42%) and circumferential resection margin positivity (22.95 vs 68.11%). Complete nodal response independently predicted improved survival (hazard ratio 0.34 (0.16–0.74). Post-chemotherapy tumour volume reduction was greater in patients with a complete nodal response (−16.3 vs −7.7 cm3, p = 0.033) with no significant difference between Mandard groups.Conclusion Patients with a complete nodal response to chemotherapy have significantly improved outcomes despite a poor Mandard score. High Mandard score does not correspond with a non-response to chemotherapy in all cases and patients with nodal downstaging may still benefit from adjuvant chemotherapy.Subject terms: Oesophageal cancer, Surgical oncology 相似文献
5.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
6.
ABSTRACTCommunication between health professionals and patients is an intergroup phenomenon where the health professional has the most power and status. Over the past few decades, there has been a steady increase in the availability to patients of information about healthcare and specific diseases on the Internet. In this paper, we ask whether the use of Internet health information assists patients to manage their consultations with health professionals better and whether it alters the intergroup dynamic by providing a more equal status for patients. In this study 370 participants from Australia and Canada completed a survey that included a ‘willingness to communicate with health professionals’ scale. They also commented on their use and trust of Internet health information. Thematic analysis suggests that patients’ use of Internet health information serves as a broker between patients and their health provider in health consultations. We discuss the implications of these findings for health practitioners as they address how easier Internet access influences patient interactions with health professionals. We consider future research directions these finding provide in explaining communication behaviour in this context. 相似文献
7.
8.
Julia H. Vermylen Gordon J. Wood Elaine R. Cohen Jeffrey H. Barsuk William C. McGaghie Diane B. Wayne 《Journal of pain and symptom management》2019,57(3):682-687
Introduction
Physician communication impacts patient outcomes. However, communication skills, especially around difficult conversations, remain suboptimal, and there is no clear way to determine the validity of entrustment decisions. The aims of this study were to 1) describe the development of a simulation-based mastery learning (SBML) curriculum for breaking bad news (BBN) conversation skills and 2) set a defensible minimum passing standard (MPS) to ensure uniform skill acquisition among learners.Innovation
An SBML BBN curriculum was developed for fourth-year medical students. An assessment tool was created to evaluate the acquisition of skills involved in a BBN conversation. Pilot testing was completed to confirm improvement in skill acquisition and set the MPS.Outcomes
A BBN assessment tool containing a 15-item checklist and six scaled items was developed. Students' checklist performance improved significantly at post-test compared to baseline (mean 65.33%, SD = 12.09% vs mean 88.67%, SD = 9.45%, P < 0.001). Students were also significantly more likely to have at least a score of 4 (on a five-point scale) for the six scaled questions at post-test. The MPS was set at 80%, requiring a score of 12 items on the checklist and at least 4 of 5 for each scaled item. Using the MPS, 30% of students would require additional training after post-testing.Comments
We developed a SBML curriculum with a comprehensive assessment of BBN skills and a defensible competency standard. Future efforts will expand the mastery model to larger cohorts and assess the impact of rigorous education on patient care outcomes. 相似文献9.